ChesebroJHKnatterudGRobertsR. Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation1987; 76: 142–54.
2.
VerstraeteMBernardRBoryM. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet1985; 1: 842–7.
3.
KorenGWeissATHasinY. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N Engl J Med1985; 313: 1384–9.
4.
AndersonJLMarshallHWSkinsJC. A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction. Circulation1984; 70: 606–18.
5.
TaylorGJMikellFLMosesHW. Intravenous versus intracoronary streptokinase therapy for acute myocardial infarction in community hospitals. Am J Cardiol1984; 54: 256–60.
6.
StackRSO'ConnorCMMarkDB. Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase. Circulation1988; 77: 151–61.
7.
SchroderRBiaminoGEnz-RudigerL. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation1983; 67: 536–48.
8.
Gruppo Italiano per lo Studio Della Streptochinasi Nell'Infarcto Miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet1986; 1: 397–401.
9.
ISIS Steering Committee. Intravenous streptokinase given within 0–4 hours of onset of myocardial infarction reduced mortality in ISIS-2 (letter). Lancet1987; 1: 502.
10.
Data on file, Genentech, Inc., South San Francisco, CA.
11.
GuerciAGerstenblithGBrinkerJ. A double-blind, placebo-controlled randomized trial of t-PA with subsequent randomization to elective PTCA for acute MI (abstract). Circulation1987; 76 (suppl IV): 259.
12.
O'RourkeMNorrisR. Improved LV ejection fraction at 21 days following coronary occlusion treated by early intravenous rt-PA infusion (abstract). J Am Coll Cardiol1988; 11: 105A.
13.
ThompsonPLRobinsonJS. Stroke after acute myocardial infarction: Relation to infarct size. Br Med J1978; 2: 457–9.
14.
KomradMSCoffeyCECoffeyKSMcKinnisRMasseyEWCaliffRM. Myocardial infarction and stroke. Neurology1984; 34: 1403–9.
15.
GarabedianHDGoldHKLeinbachRC. Comparative properties of two clinical preparations of recombinant human-tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol1987; 9: 599–607.
16.
MuellerHSRaoAKFormanSA. Thrombolysis in Myocardial Infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol1987; 10: 479–90.
17.
LiuPFlorasJHaqADetskyA. Cost-effective evaluation of thrombolytic therapy: Comparison of current modalities and identification of critical cost factors—a Canadian perspective (abstract). J Am Coll Cardiol1988; 11: 186A.
18.
TopolE. Advances in thrombolytic therapy for acute myocardial infarction. J Clin Pharmacol1987; 27: 735–45.
19.
SherryS. The FDA advisory panel's decision on rt-PA. J Clin Pharmacol1987; 27: 730–4.
